Nociceptin

What is Nociceptin?

Nociceptin — also called orphanin FQ or N/OFQ — is a 17-amino-acid endogenous neuropeptide (Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln) identified in 1995 as the natural ligand of an orphan G-protein-coupled receptor that had been cloned the year before based on sequence similarity to the classical opioid receptors. It was reported simultaneously by two independent groups: Meunier and colleagues in Nature (who named it 'nociceptin' for its pronociceptive effects in mice) and Reinscheid and colleagues in Science (who named it 'orphanin FQ' because it deorphanized the receptor and begins with Phe/F and ends with Gln/Q). Both names are used interchangeably; the receptor is now officially called the NOP receptor (nociceptin/orphanin FQ peptide receptor), formerly ORL1. Nociceptin is encoded in the prepronociceptin (PNOC) gene — the same precursor that also yields nocistatin, a second bioactive fragment with functionally opposing effects on pain. Structurally, nociceptin resembles dynorphin A (a classical kappa-opioid peptide), but it does not bind any of the mu-, delta-, or kappa-opioid receptors; it is selective for the NOP receptor, and opioid antagonists like naloxone do not block its actions. Pharmacologically, nociceptin is notorious for its paradoxical pain biology: supraspinal (intracerebroventricular) administration produces hyperalgesia, while spinal (intrathecal) administration produces analgesia. Beyond pain, the N/OFQ–NOP system has been implicated in anxiety, stress, learning and memory, reward and drug abuse, feeding, cardiovascular control, and immune function. Clinical drugs targeting the NOP receptor include cebranopadol (a mixed NOP/mu-opioid agonist in late-stage pain trials) and NOP antagonists like BTRX-246040 (LY2940094, explored in depression). Nociceptin itself is a research tool, not a therapeutic.

What Nociceptin Is Investigated For

Nociceptin is one of the most heavily studied endogenous neuropeptides in modern neuroscience — anyone encountering it is almost certainly coming from a pharmacology, pain-research, or psychiatric-drug-development angle rather than a clinical one. It is not a therapeutic; it is the molecular parent of an entire drug class. Its discovery in 1995 deorphanized the fourth member of the opioid receptor family (NOP, formerly ORL1), and the 30 years of work since have produced a remarkably coherent picture: N/OFQ modulates pain in a site-dependent way (pronociceptive supraspinally, analgesic spinally), dampens reward circuitry, affects anxiety and stress responses, impairs hippocampal learning, and tones cardiovascular and immune function. The paradoxical pain pharmacology made straightforward analgesic development difficult, but mixed NOP/mu-opioid agonists like cebranopadol — built to exploit both the analgesic and side-effect-mitigating sides of NOP activation — have advanced through late-stage human pain trials. On the psychiatric side, selective NOP antagonists like BTRX-246040 (LY2940094) showed preliminary antidepressant signals in a placebo-controlled Phase II trial. The most distinctive framing of nociceptin for anyone arriving from the nocistatin page is the twin-peptide biology: one gene, two peptides released together, opposite effects on pain. Nociceptin itself has no approved human indication, no validated self-administration protocol, and no rationale for non-clinical use; its value is as a foundational research peptide and as the biological starting point for NOP-targeted drug development.

History & Discovery

Nociceptin's discovery is a textbook example of reverse pharmacology — finding the endogenous ligand of a receptor that was cloned first and characterized after. In 1994, four independent groups (Mollereau and colleagues in France, Bunzow and colleagues in the US, Chen and colleagues, and Wang and colleagues) cloned a novel G-protein-coupled receptor from mammalian brain on the basis of sequence homology to the classical opioid receptors. The new receptor was ~50% identical in amino acid sequence to the mu-, delta-, and kappa-opioid receptors, but none of the known opioid ligands — enkephalins, endorphins, dynorphins, exogenous opioids — bound it with meaningful affinity. It was named ORL1 (opioid-receptor-like 1) and formally designated an orphan receptor. The hunt for its endogenous ligand produced one of the most dramatic simultaneous discoveries in modern neuropeptide biology. In October 1995, Meunier and colleagues in France reported in Nature the isolation of a 17-amino-acid peptide from rat brain that activated ORL1 at nanomolar concentrations and resembled dynorphin A in sequence. They observed that intracerebroventricular injection of the peptide in mice produced hyperalgesia in the hot-plate and tail-flick tests — and named it 'nociceptin' for this pronociceptive supraspinal effect. The following month, Reinscheid and colleagues in the United States reported in Science the independent isolation of the same peptide from porcine brain, identifying it through a functional assay against the related LC132 orphan receptor. They named the peptide 'orphanin FQ' — orphanin because it deorphanized the receptor, FQ because the peptide begins with phenylalanine (F) and ends with glutamine (Q). Both names persist, and the convention 'nociceptin/orphanin FQ' or 'N/OFQ' is often used to credit both groups. The receptor was renamed NOP (nociceptin/orphanin FQ peptide receptor) under International Union of Basic and Clinical Pharmacology guidelines. The following year, Nothacker and colleagues reported the structure of the prepronociceptin (PNOC) gene, revealing that nociceptin is cleaved from a 176-residue precursor protein organized similarly to preproenkephalin, preprodynorphin, and preproopiomelanocortin — the gene family that encodes the classical endogenous opioid peptides. The prepronociceptin precursor also contained flanking sequences with features of potential additional bioactive peptides. In 1998, Okuda-Ashitaka and colleagues in Japan reported in Nature that one of these sequences yielded a second bioactive peptide — nocistatin — which blocked nociceptin-induced allodynia and hyperalgesia and acted through a distinct, non-NOP receptor system. The twin-peptide biology of the PNOC gene, with nociceptin and nocistatin acting as counter-regulatory signals, is one of the most elegant examples in the field of a single gene encoding functionally opposing neuromodulators. The 30 years since the 1995 discovery have produced a remarkably broad functional literature. The paradoxical pain pharmacology (supraspinal hyperalgesia, spinal analgesia) was a defining early finding and complicated straightforward analgesic drug development. Subsequent work showed NOP involvement in anxiety, stress, learning, memory, reward, feeding, cardiovascular function, micturition, cough, and immune function. Drug discovery produced a series of NOP-selective agonists (Ro64-6198, UFP-112, SCH 221510), antagonists (J-113397, JTC-801, SB-612111, BTRX-246040/LY2940094), and mixed NOP/opioid ligands (cebranopadol). The clinical arc has been slower than initially hoped — Lambert's 2008 Nature Reviews Drug Discovery review called NOP 'a target with broad therapeutic potential' and documented early clinical programs, and by the mid-2020s cebranopadol had progressed to multiple completed Phase III pain trials while NOP-targeted programs in depression, alcohol use disorder, and cough were in various stages of development. Nociceptin itself remains a research peptide, but its discovery opened what is now a substantial therapeutic area.

How It Works

Nociceptin is a brain and spinal-cord peptide that locks onto a receptor called NOP — the fourth member of the opioid receptor family, alongside mu, delta, and kappa. Despite being structurally related to opioids, nociceptin doesn't bind any of the classical opioid receptors, and naloxone doesn't block it. The strangest thing about nociceptin is that it has opposite effects on pain depending on where it's released: in the brain it makes animals more sensitive to pain, while in the spinal cord it reduces pain. It also affects mood, anxiety, memory, and reward circuits. The body makes it from the same gene that makes nocistatin, and those two peptides generally pull in opposite directions.

Nociceptin is proteolytically released from prepronociceptin (PNOC), a 176-residue precursor protein in humans, at paired basic residues flanking the mature 17-amino-acid sequence. The same precursor also yields nocistatin (a counter-regulatory peptide) and other fragments, producing a coordinated multi-peptide output from a single gene. Nociceptin binds the NOP receptor (nociceptin/orphanin FQ peptide receptor, formerly ORL1), a Gi/Go-coupled seven-transmembrane receptor cloned in 1994 by Mollereau and colleagues on the basis of sequence homology to the mu, delta, and kappa opioid receptors (~50% identity). Despite this structural kinship, NOP does not bind classical opioids, and the classical opioid receptors do not bind nociceptin — the pharmacology of the four receptors is functionally distinct. NOP receptor activation inhibits adenylyl cyclase and cAMP accumulation, activates G-protein-coupled inwardly rectifying potassium (GIRK) channels, and inhibits voltage-gated calcium channels, producing net neuronal inhibition — the same downstream ionic effects as classical opioid receptors. The clinical consequences, however, differ because of where NOP receptors are expressed and what inputs they modulate. In the spinal cord dorsal horn, NOP activation inhibits excitatory transmission and produces analgesia and anti-allodynia, particularly in neuropathic and inflammatory pain states (Yamamoto and colleagues, 1998). Supraspinally, NOP activation in regions such as the periaqueductal gray and rostral ventromedial medulla blunts endogenous opioid-mediated pain suppression, producing a net pronociceptive effect and antagonizing stress-induced analgesia. The net result is the signature paradox of the system: intrathecal nociceptin is antinociceptive, while intracerebroventricular nociceptin is pronociceptive in rodents. Beyond pain, nociceptin impairs hippocampal learning and long-term memory formation through NOP-mediated inhibition of glutamatergic and ERK signaling (reviewed by Rekik and colleagues, 2015). In anxiety and stress circuits, the N/OFQ–NOP system has mixed effects: exogenous nociceptin tends to produce anxiolytic-like effects in some paradigms, while blockade of tonic NOP signaling (with antagonists like BTRX-246040) produces antidepressant-like and stress-resilience effects. Nociceptin modulates mesolimbic dopamine reward pathways, generally dampening the reinforcing effects of opioids, cocaine, and alcohol. It also has documented effects on cardiovascular tone (bradycardia, hypotension), micturition, cough, and immune cell function. The breadth of this pharmacology — pain, affect, memory, reward, autonomic function, immunity — is one reason NOP has been called 'a target with broad therapeutic potential.' It is also why developing selective NOP drugs has been difficult: the paradoxical pain pharmacology, species differences, and wide distribution of NOP receptors mean that both agonist and antagonist strategies carry on-target side-effect liabilities that must be carefully navigated.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Nociceptin:

• 01Why supraspinal and spinal nociceptin produce opposite effects on pain — the circuit-level explanation has been proposed (blockade of endogenous opioid stress-induced analgesia supraspinally; dorsal horn inhibition spinally) but the full molecular and network account, particularly in species closer to humans, remains incomplete.
• 02Species differences in the direction of supraspinal nociceptin effects — rodents show supraspinal hyperalgesia while non-human primates can show antinociception, and the translational implications for NOP-targeted drug development in humans are not fully resolved.
• 03The role of tonic endogenous N/OFQ–NOP signaling in mood disorders — the BTRX-246040 depression trial suggested a real effect, but the mechanism (stress resilience, reward-circuit modulation, direct antidepressant action) and the patient populations most likely to benefit are not characterized.
• 04Whether NOP-selective agonists can be developed as non-abusable analgesics without mu-opioid activity — cebranopadol's clinical success is partly attributed to its mixed NOP/mu profile, and whether pure NOP agonism delivers comparable analgesia in humans is an open question.
• 05The human pharmacology of the broader PNOC-derived peptide family — nocistatin's receptor is uncharacterized, and whether other prepronociceptin-derived fragments have additional bioactivity in humans is not settled.
• 06The immunological and peripheral roles of the N/OFQ–NOP system — animal and in vitro data implicate NOP signaling in immune cell function, cardiovascular tone, and micturition, but the clinical relevance in humans is largely unexplored.

Forms & Administration

Research use only. Nociceptin is commercially available as a research-grade peptide from standard peptide vendors and reference-standard suppliers. In preclinical studies, it is administered by intrathecal, intracerebroventricular, or direct brain-region microinjection in anesthetized rodents, or applied to tissue preparations and cultured cells. There is no approved human formulation, no validated peripheral route of administration that reaches CNS NOP receptors at pharmacologically relevant concentrations, and no commercial therapeutic product based on the peptide itself. Therapeutic relevance is instead pursued through small-molecule and modified-peptide ligands of the NOP receptor (cebranopadol, BTRX-246040, others) in formal pharmaceutical development.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions